Read about our COVID-19 Response. Blood Matters Mission and Values Blood Matters Leadership Board of Directors Careers Map and Directions Cerus’ new corporate brand is inspired by its unwavering commitment to blood safety and availability for improved patient outcomes. With a nearly three-decade history in the field of transfusion medicine, Cerus is looking to use its new Blood Matters campaign to further refine its corporate identity as the market leader and innovation engine for pathogen reduction technologies. Updating its corporate brand provides the opportunity to build upon this established expertise, while emphasizing Cerus’ long-term strategy to develop next-generation technologies, to expand its portfolio of blood products. Cerus’ new brand campaign demonstrates its dedication to: Safeguarding the World’s Blood Supply Chronic blood shortages, emerging pathogens and increasing risks of transfusion-associated infections have heightened the need for blood safety and availability. Cerus is dedicated solely to safeguarding the world’s blood supply and providing innovative solutions to improve blood safety, access and patient survival. Offering Inventive Solutions for Blood Safety and Access Cerus’ INTERCEPT Blood System is the leading pathogen reduction technology for ensuring the safety of the blood supply. We are taking advantage of the most extensive scientific and clinical data in the blood transfusion space to develop next generation technologies to expand our portfolio of blood products. Enhancing Our Partners’ Operations and Reputation We collaborate and partner with many of the world’s leading blood centers and hospitals and are committed to their success. By applying our expertise in all aspects of the blood supply chain we help them become more proficient in achieving our shared goal of improved patient care. Making a Lasting Impact on Patients Around the World At Cerus, blood safety is personal because protecting patient health and well-being is why we exist. Our passion drives us to go the extra mile so that patients everywhere can have access to safe blood in their time of need. In addition to the new brand campaign, Cerus has recently moved and consolidated its corporate offices to a new facility in Concord California. The new location will provide a basis for future expansion, greater teamwork and communication as the business grows enabling Cerus to execute on its mission to establish INTERCEPT as the standard of care for transfused components Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2020 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.1.0 About Cerus About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK